Developer docs
API playgroundTry for free, no card

Search company profiles

bit.bio

Full company profile

uuid0000hlk

Namestring
bit.bio
Legal namestring
Bit Bio Limited
Websiteurl
bit.bio
Company typeenum
Private
Founded yearint
2016
Descriptiontext

bit.bio is a Cambridge, UK-based synthetic biology company founded in 2016 that develops engineered human cell products and platform services for biomedical research, drug discovery, and preclinical safety testing. Its core technology, opti-ox, is a deterministic cell programming platform that uses inducible transcription factor expression integrated into the AAVS1 genomic safe harbour to convert human induced pluripotent stem cells (iPSCs) into specified cell types within days, with reported capacity to produce up to two billion homogeneous cells per batch in 10-14 days. The company monetizes this platform through its ioCells product portfolio — cryopreserved iPSC-derived cell lines spanning neurons (glutamatergic, GABAergic, motor, sensory), glia (astrocytes, microglia, oligodendrocyte-like cells), skeletal myocytes, hepatocytes, plus disease models, fluorescent ioTracker variants, and CRISPR-Ready Cas9-expressing lines — sold via direct e-commerce at €999 per 3-vial pack with volume and academic pricing tiers, alongside custom cell development and disease modeling services for enterprise clients.

The company serves three primary customer segments — academic researchers, biotechnology companies, and pharmaceutical/CRO enterprises (including Charles River Laboratories and Evotec) — with named academic users spanning King's College London, UCL, Cardiff University, Loughborough University, and DZNE/Charité. Its go-to-market combines product-led e-commerce with an enterprise sales layer for large-volume and custom orders, supported by dual US and European distribution hubs (the latter via a SciSafe partnership established February 2026) and a multi-channel marketing strategy anchored by the annual Human Cell Forum conference in Cambridge. Founded with venture backing and now reportedly having raised approximately $622 million across six rounds (most recently a $50 million Series C led by M&G Investments in January 2026), bit.bio operates through wholly-owned subsidiaries in the UK (Bit Bio Limited), US (Bit Bio Inc., Pleasanton, CA), and Austria (Bit Bio Discovery GmbH, Vienna). The company is widely reported to be positioning for a potential IPO following the January 2026 Series C and the appointment of Lord David Prior as Board Chair.

Short descriptiontext

Cambridge-based synthetic biology company that develops engineered human iPSC-derived cell products (ioCells) using proprietary opti-ox deterministic reprogramming technology, serving academic researchers, biotech firms, and pharmaceutical companies in drug discovery and preclinical safety testing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
iPSC-derived cells, cell programming technology, disease model cells, drug discovery tools, CRISPR-ready cells
Industry3 codes
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Stem Cell-Based Research Products
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1ioCells Product Sales
TypeOne Time License
Description

bit.bio generates revenue through the sale of cryopreserved human iPSC-derived cells (ioCells) to researchers in academia, biotech, and pharma. Products include ioWild Type Cells, ioDisease Model Cells, ioTracker Cells, and CRISPR-Ready ioCells. Volume discounts and academic pricing are available. The company also offers custom cell development services for bespoke disease models or reporter lines.

bit.bio
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Pricing details4 tiers
1Standard pricing for CNS portfolio (3-vial packs)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Most products within CNS portfolio available in three-vial packs for €999. Some products offered in two-vial packs for the same price point.

bit.bio
2Volume discount tier (10-33 packs)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Automatic 10% discount for orders of 10-33 packs (30-99 vials).

bit.bio
3Enterprise volume pricing (>34 packs)
ModelUnit PricingBilling cadenceMulti-year contract
Notes

>100 vials available with custom quote pricing for large-scale orders.

bit.bio
4Academic pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Academic users can purchase any ioCells in 3-vial packs at €999 per pack, available year-round with any cell type combination.

bit.bio
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1ioCells
Description

Portfolio of deterministically programmed human iPSC-derived cells for research and drug discovery

bit.bio
+7 more records
Core offering1 text field

bit.bio manufactures and sells engineered human iPSC-derived cell products (ioCells) and provides related custom cell development and CRISPR screening services for biomedical research, drug discovery, and preclinical development. The company uses its proprietary opti-ox deterministic cell programming platform to produce consistent, scalable batches of human neurons, glia, muscle, and liver cells, including wild-type, disease model, fluorescent reporter, and CRISPR-ready variants.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Can produce up to two billion homogeneous human iPSC-derived cells in 10-14 days
+3 more records
Product and service10 records
1ioHepatocytes
CategoryHuman Liver Cells
Description

Human iPSC-derived hepatocytes for liver safety testing, hepatotoxicity studies, and drug discovery, sold as cryopreserved vials to researchers in pharma, biotech, and academia.

2ioSkeletal Myocytes
CategoryHuman Muscle Cells
Description

Human iPSC-derived skeletal muscle cells for muscle disease modelling, drug screening, and cell therapy research, sold as cryopreserved vials.

3ioGABAergic Neurons
CategoryHuman Neuronal Cells
Description

Human iPSC-derived inhibitory GABAergic neurons for neuroscience research, electrophysiology, and CNS drug discovery.

4ioGlutamatergic Neurons
CategoryHuman Neuronal Cells
Description

Human iPSC-derived excitatory glutamatergic neurons used for CNS drug discovery, neurotoxicity testing, and disease modelling by pharma and academic researchers.

5ioMotor Neurons
CategoryHuman Neuronal Cells
Description

Human iPSC-derived motor neurons for motor neuron disease research, including ALS, SMA, and neurodegenerative disease drug screening.

6ioSensory Neurons
CategoryHuman Neuronal Cells
Description

Human iPSC-derived sensory neurons for pain research, neuropathy modelling, and sensory neuron drug screening.

7ioAstrocytes
CategoryHuman Glial Cells
Description

Human iPSC-derived astrocytes for CNS co-culture models, calcium imaging, and neurodegeneration research.

8ioMicroglia
CategoryHuman Glial Cells
Description

Human iPSC-derived microglia cells for neuroinflammation research, phagocytosis assays, cytokine release studies, and CNS drug discovery.

9ioOPC & ioOligodendrocyte-like cells
CategoryHuman Glial Cells
Description

Human iPSC-derived oligodendrocyte precursor cells and oligodendrocyte-like cells for myelination studies, drug screening, and multiple sclerosis research.

10ioDisease Model Cells
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1SciSafe, Inc.
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-19
Description

Partnership for European Distribution Hub enabling next-working-day delivery across the EU with reduced lead times, lower logistics costs, and removal of customs burden for customers. SciSafe provides cGMP-compliant biopharma storage and logistics services.

businesswire.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership to commercialise CL1, the world's first hybrid biological computer combining silicon circuitry with 800,000 human neurons grown on a chip. The biological machine builds on Cortical Labs' DishBrain prototype and leverages bit.bio's human neurons for applications in medical research, drug testing, and neuroscience.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Strategic customer and research partner using ioCells (ioGlutamatergic Neurons, ioMicroglia, ioOligodendrocyte-like cells) for drug discovery and preclinical research services. Charles River provides validated protocols and assay development using bit.bio products.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

REPROCELL provides iPSC-derived cell products, stem cell banking, and drug-discovery services. It is a directly comparable vendor offering iPSC-derived hepatocytes, neurons, and other cell types to pharma and academic researchers similar to bit.bio's ioCells line.

2Corning Life Sciences
TypeBroad incumbent
Description

Corning supplies cell culture vessels, extracellular matrices, and increasingly primary/derived cell products through its Life Sciences segment. It competes with bit.bio in providing scalable, reproducible cell culture workflows to pharma and academic customers.

TypeEmerging player
Description

Cell Signaling Technology is primarily an antibody and assay vendor but has expanded into cell-based reagents and CRISPR tools that overlap with bit.bio's CRISPR-Ready ioCells and assay-supporting product lines for translational researchers.

TypeDirect peer
Description

FUJIFILM's CDI is the longest-established commercial producer of iPSC-derived human cells used in drug discovery, toxicology, and cell therapy development. Both companies compete head-to-head in iPSC-derived hepatocytes, cardiomyocytes, neurons, and other differentiated cell types sold to pharma and academic customers.

TypeDirect peer
Description

STEMCELL Technologies is a leading specialty supplier of reagents, media, and primary/iPSC-derived cell products for biomedical research. It overlaps with bit.bio's academic and biotech customer base in stem-cell research tools, disease modelling reagents, and organoid culture workflows.

TypeBroad incumbent
Description

Through its Gibco portfolio, Thermo Fisher is the largest life-science tools supplier with deep reach into academic and pharma cell culture workflows. While not a pure-play iPSC cell product competitor, it offers differentiated media, primary cells, and increasingly iPSC-derived products that compete with bit.bio's offerings and have stronger bundled selling motions.

TypeBroad incumbent
Description

Lonza operates a large cell-and-gene-therapies services franchise spanning iPSC process development, cell manufacturing, and primary/derived cell products. Its scale, GMP manufacturing footprint, and pharma relationships make it a strategic competitor in cell-based research tools and contract cell supply.

TypeDirect peer
Description

Ncardia produces iPSC-derived cardiomyocytes, neurons, and other cell types for cardiac safety and neuro drug discovery. It competes with bit.bio's disease models and CNS offerings, particularly for pharma customers running high-throughput safety and efficacy assays.

TypeDirect peer
Description

BrainXell is a specialty provider of iPSC-derived neurons (dopaminergic, GABAergic, motor, sensory) for neurological disease modelling and drug discovery. It is directly comparable to bit.bio's CNS portfolio and targets similar pharma and academic customers.

TypeDirect peer
Description

Axol Bioscience specialises in iPSC-derived human neural cell types (neurons, astrocytes, microglia) for disease modelling and drug discovery, closely mirroring bit.bio's CNS-heavy product portfolio and serving overlapping pharma and academic customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

bit.bio

Stem Cell-Based Research Productsbit.bio

Cambridge-based synthetic biology company that develops engineered human iPSC-derived cell products (ioCells) using proprietary opti-ox deterministic reprogramming technology, serving academic researchers, biotech firms, and pharmaceutical companies in drug discovery and preclinical safety testing.

What bit.bio does

bit.bio is a Cambridge, UK-based synthetic biology company founded in 2016 that develops engineered human cell products and platform services for biomedical research, drug discovery, and preclinical safety testing. Its core technology, opti-ox, is a deterministic cell programming platform that uses inducible transcription factor expression integrated into the AAVS1 genomic safe harbour to convert human induced pluripotent stem cells (iPSCs) into specified cell types within days, with reported capacity to produce up to two billion homogeneous cells per batch in 10-14 days. The company monetizes this platform through its ioCells product portfolio — cryopreserved iPSC-derived cell lines spanning neurons (glutamatergic, GABAergic, motor, sensory), glia (astrocytes, microglia, oligodendrocyte-like cells), skeletal myocytes, hepatocytes, plus disease models, fluorescent ioTracker variants, and CRISPR-Ready Cas9-expressing lines — sold via direct e-commerce at €999 per 3-vial pack with volume and academic pricing tiers, alongside custom cell development and disease modeling services for enterprise clients.

The company serves three primary customer segments — academic researchers, biotechnology companies, and pharmaceutical/CRO enterprises (including Charles River Laboratories and Evotec) — with named academic users spanning King's College London, UCL, Cardiff University, Loughborough University, and DZNE/Charité. Its go-to-market combines product-led e-commerce with an enterprise sales layer for large-volume and custom orders, supported by dual US and European distribution hubs (the latter via a SciSafe partnership established February 2026) and a multi-channel marketing strategy anchored by the annual Human Cell Forum conference in Cambridge. Founded with venture backing and now reportedly having raised approximately $622 million across six rounds (most recently a $50 million Series C led by M&G Investments in January 2026), bit.bio operates through wholly-owned subsidiaries in the UK (Bit Bio Limited), US (Bit Bio Inc., Pleasanton, CA), and Austria (Bit Bio Discovery GmbH, Vienna). The company is widely reported to be positioning for a potential IPO following the January 2026 Series C and the appointment of Lord David Prior as Board Chair.

bit.bio firmographics

Firmographics
Name
bit.bio
Legal name
Bit Bio Limited
Website
https://bit.bio
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
101–250 employees
Short description
Cambridge-based synthetic biology company that develops engineered human iPSC-derived cell products (ioCells) using proprietary opti-ox deterministic reprogramming technology, serving academic researchers, biotech firms, and pharmaceutical companies in drug discovery and preclinical safety testing.
Ownership category
akta.pro rank

bit.bio industry classification

Industry
Product category
Stem Cell-Based Research Products
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • IPSC-derived cells
  • Cell programming technology
  • Disease model cells
  • Drug discovery tools
  • CRISPR-ready cells

Where bit.bio is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices4 records

Markets served

bit.bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. ioCells Product Sales: bit.bio generates revenue through the sale of cryopreserved human iPSC-derived cells (ioCells) to researchers in academia, biotech, and pharma. Products include ioWild Type Cells, ioDisease Model Cells, ioTracker Cells, and CRISPR-Ready ioCells. Volume discounts and academic pricing are available. The company also offers custom cell development services for bespoke disease models or reporter lines.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goStandard pricing for CNS portfolio (3-vial packs)
Unit PricingPay-as-you-goVolume discount tier (10-33 packs)
Unit PricingMulti-year contractEnterprise volume pricing (>34 packs)
Unit PricingPay-as-you-goAcademic pricing

Go-to-market motion2 records

Distribution channels5 records

Marketing channels8 records

bit.bio product offering

Product offering

Core offering

bit.bio manufactures and sells engineered human iPSC-derived cell products (ioCells) and provides related custom cell development and CRISPR screening services for biomedical research, drug discovery, and preclinical development. The company uses its proprietary opti-ox deterministic cell programming platform to produce consistent, scalable batches of human neurons, glia, muscle, and liver cells, including wild-type, disease model, fluorescent reporter, and CRISPR-ready variants.

Differentiator

Problem solved

Functional benefit

Brands

  • ioCells: Portfolio of deterministically programmed human iPSC-derived cells for research and drug discovery
  • ioWild Type Cells
  • ioDisease Model Cells
  • CRISPR-Ready ioCells
  • ioTracker Cells
  • opti-ox
  • DIGICELL
  • OPTI-OX

Products and services

  • ioHepatocytes Human iPSC-derived hepatocytes for liver safety testing, hepatotoxicity studies, and drug discovery, sold as cryopreserved vials to researchers in pharma, biotech, and academia.
  • ioSkeletal Myocytes Human iPSC-derived skeletal muscle cells for muscle disease modelling, drug screening, and cell therapy research, sold as cryopreserved vials.
  • ioGABAergic Neurons Human iPSC-derived inhibitory GABAergic neurons for neuroscience research, electrophysiology, and CNS drug discovery.
  • ioGlutamatergic Neurons Human iPSC-derived excitatory glutamatergic neurons used for CNS drug discovery, neurotoxicity testing, and disease modelling by pharma and academic researchers.
  • ioMotor Neurons Human iPSC-derived motor neurons for motor neuron disease research, including ALS, SMA, and neurodegenerative disease drug screening.
  • ioSensory Neurons Human iPSC-derived sensory neurons for pain research, neuropathy modelling, and sensory neuron drug screening.
  • ioAstrocytes Human iPSC-derived astrocytes for CNS co-culture models, calcium imaging, and neurodegeneration research.
  • ioMicroglia Human iPSC-derived microglia cells for neuroinflammation research, phagocytosis assays, cytokine release studies, and CNS drug discovery.
  • ioOPC & ioOligodendrocyte-like cells Human iPSC-derived oligodendrocyte precursor cells and oligodendrocyte-like cells for myelination studies, drug screening, and multiple sclerosis research.
  • ioDisease Model Cells

Quantifiable outcome

  • Can produce up to two billion homogeneous human iPSC-derived cells in 10-14 days
  • +3 more outcomes

Companies that use bit.bio

Customer profile

Named customers12 records

Segments4 records

Ideal customer profiles4 records

bit.bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

bit.bio partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • SciSafe, Inc.coreChannel Partner/ Reseller/ Distributor · 19 February 2026Partnership for European Distribution Hub enabling next-working-day delivery across the EU with reduced lead times, lower logistics costs, and removal of customs burden for customers. SciSafe provides cGMP-compliant biopharma storage and logistics services.
  • Cortical LabscoreStrategic or Co-development PartnerPartnership to commercialise CL1, the world's first hybrid biological computer combining silicon circuitry with 800,000 human neurons grown on a chip. The biological machine builds on Cortical Labs' DishBrain prototype and leverages bit.bio's human neurons for applications in medical research, drug testing, and neuroscience.
  • Charles River LaboratoriescoreChannel Partner/ Reseller/ DistributorStrategic customer and research partner using ioCells (ioGlutamatergic Neurons, ioMicroglia, ioOligodendrocyte-like cells) for drug discovery and preclinical research services. Charles River provides validated protocols and assay development using bit.bio products.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

bit.bio competitors and assessment

Company assessment

Direct peers

  • REPROCELL: REPROCELL provides iPSC-derived cell products, stem cell banking, and drug-discovery services. It is a directly comparable vendor offering iPSC-derived hepatocytes, neurons, and other cell types to pharma and academic researchers similar to bit.bio's ioCells line.
  • FUJIFILM Cellular Dynamics International: FUJIFILM's CDI is the longest-established commercial producer of iPSC-derived human cells used in drug discovery, toxicology, and cell therapy development. Both companies compete head-to-head in iPSC-derived hepatocytes, cardiomyocytes, neurons, and other differentiated cell types sold to pharma and academic customers.
  • STEMCELL Technologies: STEMCELL Technologies is a leading specialty supplier of reagents, media, and primary/iPSC-derived cell products for biomedical research. It overlaps with bit.bio's academic and biotech customer base in stem-cell research tools, disease modelling reagents, and organoid culture workflows.
  • Ncardia: Ncardia produces iPSC-derived cardiomyocytes, neurons, and other cell types for cardiac safety and neuro drug discovery. It competes with bit.bio's disease models and CNS offerings, particularly for pharma customers running high-throughput safety and efficacy assays.
  • BrainXell: BrainXell is a specialty provider of iPSC-derived neurons (dopaminergic, GABAergic, motor, sensory) for neurological disease modelling and drug discovery. It is directly comparable to bit.bio's CNS portfolio and targets similar pharma and academic customers.
  • Axol Bioscience: Axol Bioscience specialises in iPSC-derived human neural cell types (neurons, astrocytes, microglia) for disease modelling and drug discovery, closely mirroring bit.bio's CNS-heavy product portfolio and serving overlapping pharma and academic customers.

Broad incumbents

  • Corning Life Sciences: Corning supplies cell culture vessels, extracellular matrices, and increasingly primary/derived cell products through its Life Sciences segment. It competes with bit.bio in providing scalable, reproducible cell culture workflows to pharma and academic customers.
  • Thermo Fisher Scientific (Gibco Cell Culture): Through its Gibco portfolio, Thermo Fisher is the largest life-science tools supplier with deep reach into academic and pharma cell culture workflows. While not a pure-play iPSC cell product competitor, it offers differentiated media, primary cells, and increasingly iPSC-derived products that compete with bit.bio's offerings and have stronger bundled selling motions.
  • Lonza: Lonza operates a large cell-and-gene-therapies services franchise spanning iPSC process development, cell manufacturing, and primary/derived cell products. Its scale, GMP manufacturing footprint, and pharma relationships make it a strategic competitor in cell-based research tools and contract cell supply.

Emerging players

  • Cell Signaling Technology: Cell Signaling Technology is primarily an antibody and assay vendor but has expanded into cell-based reagents and CRISPR tools that overlap with bit.bio's CRISPR-Ready ioCells and assay-supporting product lines for translational researchers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

bit.bio social profiles

Digital presence

bit.bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

bit.bio leadership team

Management profile

Number of profiles

Profiles14 records

bit.bio subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

bit.bio funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

bit.bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about bit.bio

What does bit.bio do?

bit.bio manufactures and sells engineered human iPSC-derived cell products (ioCells) and provides related custom cell development and CRISPR screening services for biomedical research, drug discovery, and preclinical development. The company uses its proprietary opti-ox deterministic cell programming platform to produce consistent, scalable batches of human neurons, glia, muscle, and liver cells, including wild-type, disease model, fluorescent reporter, and CRISPR-ready variants.

Is bit.bio a public or private company?

bit.bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was bit.bio founded?

bit.bio was founded in 2016. It employs 101 to 250 people.

Where is bit.bio based?

bit.bio is headquartered in Cambridge, United Kingdom, in the Europe region.

How does bit.bio make money?

One revenue line is on record: ioCells Product Sales.

Who are bit.bio's main competitors?

Direct peers on record are REPROCELL, FUJIFILM Cellular Dynamics International, STEMCELL Technologies, Ncardia, BrainXell and Axol Bioscience. Broad incumbents are Corning Life Sciences, Thermo Fisher Scientific (Gibco Cell Culture) and Lonza. Cell Signaling Technology is listed as an emerging player.

Does bit.bio have an API?

No public API is recorded for bit.bio.

What industry is bit.bio in?

bit.bio's product category is Stem Cell-Based Research Products. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0bit.bio Raises $25 Million In Series D Funding As Human Cell Model Demand Surges 76%bit.bio raised $25 million in Series D funding to expand its human cell model portfolio. The company reports record demand, with paid vial volumes up 76% year to date in 2026. It plans to use the capital to introduce new cell types and expand access.Startup Researcherbit.bio Raises $25 Million Series Dbit.bio raised $25 million in Series D funding, led by M&G Investments and Dr. Jonathan Milner. The company's paid vial volumes rose 76% year to date, and orders increased 34%. The capital will fund portfolio expansion and wider customer access.BitlyHuman cell programming company bit.bio closes $25M Series Dbit.bio raised $25 million in Series D funding to expand its human cell models for drug discovery and research. The company's opti-ox platform produces consistent cell types, and the funding will support portfolio expansion and wider access. The company plans to use the funds to increase availability of its models.BusinessCloudHuman cell manufacturer bit.bio wins £19m backingbit.bio secured $25 million in Series D funding, with paid vial volumes up 76% in 2026. Orders rose 34% and active customers 40%, including 63% growth in academic customers. The company aims to expand its cell portfolio and global access.Bitbit.bio secures $25 million as demand for its human cell models reaches record levelsbit.bio raised $25 million in Series D funding, with paid vial volumes up 76% year to date in 2026. Orders rose 34% and active customers up 40%, including 63% growth in academic customers. The company will use the funds to expand its human cell portfolio and customer access.Pharmafilebit.bio expands human heart cell portfolio through myriamed partnershipbit.bio partnered with myriamed to offer cryopreserved iPSC-derived cardiomyocytes for drug discovery and safety testing. The cells include ventricular and atrial cardiomyocytes, a dilated cardiomyopathy disease model, and reporter cardiac cells, available through bit.bio's CRISPR screening services. The partnership expands bit.bio's human cell portfolio across heart, liver, and CNS.The future of tradingbit.bio partners with myriamed to add iPSC-derived cardiomyocytes to drug discovery portfoliobit.bio entered an exclusive partnership with Germany's myriamed to add human iPSC-derived cardiomyocytes to its drug discovery portfolio. The deal expands its human cell offering to three key drug-safety organ systems, including cryopreserved ventricular and atrial cardiomyocytes and a dilated cardiomyopathy model. The partnership was announced on Sept. 23, 2026.BusinessCloudGrowing Cambridge MedTech appoints first CTOCambridge MedTech company bit.bio has appointed Sejla Salic-Hainzl as its first chief technology officer while simultaneously launching the ioScreen platform for human cell-based drug discovery. The new CRISPR screening service is designed to accelerate functional genomics research by allowing scientists to modulate gene activity without requiring specialized expertise.Silicon RepublicThe coded cells redefining research and drug discoveryDr Emma Pepperell, a scientist with roots in veterinary medicine and pharmacology, has been appointed CEO of UK-based biotechnology company Bit.Bio, which specializes in reprogramming human cells for drug discovery and disease research. The company enables researchers to direct stem cells to become specific cell types such as neurons, liver cells, or heart cells, allowing pharmaceutical companies to study drug interactions without relying on traditional animal models. Bit.Bio recently hosted a Human Cell Forum bringing together scientists to share advances in non-animal testing methodologies, which are increasingly required by regulatory bodies like the FDA.AETOSWireParse Biosciences and bit.bio Announce Landmark AllianceParse Biosciences and bit.bio announced an alliance to map transcription factor-driven cell identity, combining bit.bio's cell programming technology with Parse's single cell sequencing. The partnership aims to build a foundational dataset for predictive drug discovery and human cell manufacturing at scale.